Source: Eur Respir J, 58 (5) 2100759; 10.1183/13993003.00759-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Kosuke Kato, Yoon-Joo Shin, Sunny Palumbo, Ioannis Papageorgiou, Seongmin Hahn, Joseph D. Irish, Skye P. Rounseville, Robert T. Krafty, Lutz Wollin, Maor Sauler, Louise Hecker. Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing. Eur Respir J, 58 (5) 2100759; 10.1183/13993003.00759-2021

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes Source: Eur Respir J, 55 (4) 2000105; 10.1183/13993003.00105-2020 Year: 2020 LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes Source: Eur Respir J, 55 (1) 1900647; 10.1183/13993003.00647-2019 Year: 2020 Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? Source: Eur Respir Rev 2011; 20: 201-207 Year: 2011 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Evolution of biomechanical changes in a murine model of bleomycin-induced lung fibrosis: inflammation versus fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 396s Year: 2006 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021 Year: 2021 Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 Year: 2017